Skip to main content

Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Objective

Deregulation of CXCL12 signaling via the CXCR4 chemokine receptor plays a key role in many diseases, including cancer, rheumatoid arthritis, chronic inflammation and cardiovascular disorders. Thus, agents modulating CXCR4 signaling offer many prospects for therapeutic development. CXCR4 is also a major coreceptor for HIV entry. Thus, we used HIV as tool to screen peptide libraries encompassing the entire blood peptidome for novel CXCR4 ligands. This approach allowed the identification of a small fragment of human serum albumin as potent HIV inhibitor. Remarkably, this naturally occurring peptide, named EPI-X4 (Endogenous Peptide Inhibitor of CXCR4), blocks CXCL12/CXCR4 signaling and suppresses cancer cell migration and invasion. Preclinical studies in mice show that EPI-X4 mobilizes hematopoietic stem/progenitor cells and inhibits lung inflammation in an asthma model. Preliminary analyses suggest that EPI-X4 is more specific and better tolerated than Mozobiol® (AMD3100), the only CXCR4 antagonist approved for clinical application. Recently, we developed synthetic derivatives of EPI-X4 showing about three orders of magnitude improved potency against HIV as well as increased plasma stability. Key goals of this project are to determine the therapeutic potential of these improved derivatives against cancers (Aim 1) and inflammatory diseases (Aim 2) using established mouse models of colon carcinoma, osteosarcoma, glioblastoma, airway inflammation and dermatitis. These disorders were selected from the large number of CXCR4-linked diseases because no safe and effective treatment exists and since preclinical mouse models are available to determine whether EPI-X4 derived agents are more efficient and better tolerated than other compounds. In parallel to the experimental assessment of the therapeutic potential of these novel CXCR4 antagonists, we will perform market analyses and develop an IPR strategy to pave the way towards commercialization and future clinical application.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/health sciences/inflammatory diseases
  • /social sciences/sociology/social problems/migration
  • /medical and health sciences/clinical medicine/pneumology/asthma
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

ERC-2018-PoC
See other projects for this call

Funding Scheme

ERC-POC - Proof of Concept Grant

Host institution

UNIVERSITAET ULM
Address
Helmholtzstrasse 16
89081 Ulm
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 95 256

Beneficiaries (3)

UNIVERSITAET ULM
Germany
EU contribution
€ 95 256
Address
Helmholtzstrasse 16
89081 Ulm
Activity type
Higher or Secondary Education Establishments
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 26 950
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
UNIVERSITE DE STRASBOURG
France
EU contribution
€ 26 950
Address
Rue Blaise Pascal 4
67081 Strasbourg
Activity type
Higher or Secondary Education Establishments